Travere Therapeutics (TVTX) Tops Q4 EPS by 31c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. SPY
5. META
6. MSFT
7. USO
8. AMD
9. GMAB
10. ATH

Go back to Travere Therapeutics (TVTX) Tops Q4 EPS by 31c

Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

February 23, 2023 4:01 PM EST

Recently received U.S. FDA accelerated approval of FILSPARI (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy (IgAN)

European Medicines Agency (EMA) review decision for potential conditional approval of sparsentan in IgAN anticipated in second half of 2023

Pivotal DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) on track to report topline data from confirmatory two-year endpoints in second quarter of 2023

Net product sales of $52 million for the fourth quarter of 2022; $201 million for the full year... More